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CASE REPORT
The variability of cardiovascular abnormalities is one of the characteristics of systemic lupus erythematosus
(SLE). Among the cardiovascular manifestations, hypertension is reported in 14% to 58.1% of patients in diverse
ethnic populations, and remains a clinically important issue due to its close relationship with early mortality in
patients with SLE. The development of hypertension in patients with SLE has been associated with advanced
lupus-related renal disease and the medications used for the treatment of lupus. Malignant hypertension is a
serious complication of hypertension; it rarely occurs in patients with SLE. However, it can occur in patients with
other complicated medical conditions such as the antiphospholipid antibody syndrome (APS) or cardiac
tamponade. Here, we report the case of a patient with SLE and malignant hypertension with hypertensive
retinopathy that initially presented without clinical evidence of APS or hypertensive nephropathy. (Korean J Intern
Med 2010;25:341-344)
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a systemic
autoimmune disease that is characterized by a wide
spectrum of clinical manifestations, including renal,
pulmonary, cardiovascular, and neuropsychiatric
abnormalities [1]. In particular, cardiovascular mani-
festations such as myocarditis, valvular heart disease,
pericardial effusion, coronary heart disease, and systemic
hypertension have been widely recognized in patients with
SLE. 
Keith et al. [2] initially described malignant hyper-
tension as a disease entity. Prior to the development of
effective anti-hypertensive drugs, malignant hypertension
lead to death within about one year after diagnosis. However,
the incidence and mortality of malignant hypertension
has declined since the development of new therapeutic
strategies, including artificial renal replacement therapy
and novel medications that are capable of effectively
controlling hypertension-related mechanisms or pathways
[3]. Malignant hypertension may develop with either
essential or secondary hypertension resulting from the
underlying or as a disease complication. The main causes
of secondary malignant hypertension are thought to be
parenchymal renal or renovascular lesions irrespective of
the underlying disease [3]. Malignant hypertension has
been reported in association with autoimmune rheumatic
diseases and in patients with the antiphospholipid antibody
syndrome (APS) alone or with SLE and is relatively well
described in the medical literature [4]. However,
malignant hypertension as the initial presentation of SLE,
alone without APS, has not been previously reported.
Here, we report a case of lupus nephritis presenting with
malignant hypertension, without clinically evident APS,
and hypertensive nephrosclerosis on renal biopsy. 342 The Korean Journal of Internal Medicine Vol. 25, No. 3, September 2010
CASE REPORT
A 38-year-old woman was referred for the evaluation
of visual disturbance and headache lasting for over
3 weeks. Two weeks prior to her visit to our clinic, the
patient complained of myalgia, cough and non-productive
sputum without clearly identifiable causes. In addition,
the visual disturbance and headache were worsening.
The patient visited the department of ophthalmology for
the visual disturbance, and was diagnosed with hyper-
tensive retinopathy. Anithypertensive medications were
prescribed.  
The physical examination at the initial visit revealed
high blood pressure, 190/110 mmHg, a respiration rate of
25/min and a heart rate of 113 beats/min. The breath
sounds at the left lung field were decreased and mild
pitting edema of both lower extremities was noted. 
The laboratory studies included a complete blood count
and acute phase reactants, the results showed: white
blood count 3,700/mm3, hemoglobin 9.4 g/dL, platelets
12,700/dL, erythrocyte sediment rate 50 mm/hr (normal
< 20 mm/hr), and C-reactive protein 8.5 mg/dL (normal
< 0.5 mg/dL). Routine chemistry revealed some abnormal
results, including a total protein 6.9 g/dL, albumin 2.8
g/dL, creatinine 1.6 mg/dL (normal < 1.5 mg/dL), and
cholesterol 202 mg/dL. Immunological screening for
autoimmune diseases showed an antinuclear antibody
(ANA) titer of 1:320 with a speckled pattern, and 56.10
IU/mL of antibody to anti-double-stranded DNA (normal
< 5 IU/mL). The complement levels were decreased to
37.9 mg/dL for C3 and 4.3 mg/dL for C4. Tests for the
lupus anticoagulant, anti-cardiolipin antibody of IgM, IgG
and IgA, anti β2-glycoprotein1 (β2-GP1), and venereal
disease research laboratory test (VDRL) were all negative.
The initial urinalysis showed albumin 2+, red blood cell
count > 30/HPF and WBC 1 to 3/HPF in a spot urine.
Significant proteinuria of 6,489 mg was calculated in the
24-hour urine. Plain chest radiography showed
cardiomegaly with a moderate left pleural effusion. Renal
arterial stenosis was not detected on the computed
tomography angiography of the abdomen. The findings of
the transthoracic echocardiography revealed a small to
moderate pericardial effusion, large left pleural effusion
with fibrinous material, enlargement of the left atrium,
and left ventricular concentric hypertrophy. On the
fundoscopic examination, serious retinal detachment,
cotton-wool spots and retinal hemorrhages, of both eyes
were, compatible with a hypertensive retinopathy grade
III (Fig. 1A). Magnetic resonance imaging with angiography
of the brain showed no definite abnormal findings.
The patient was diagnosed with SLE based on the
clinical features and laboratory results including the ANA,
pleural and pericardial serositis, anti-dsDNA, and renal
involvement with massive proteinuria; the findings
fulfilled the American College of Rheumatology classi-
fication criteria for the diagnosis of SLE [5]. The patient
also met the World Health Organization (WHO) criteria
for malignant hypertension. The renal biopsy revealed a
membranous lupus nephritis according to the WHO
histopathology criteria; there was no evidence of hyper-
tensive nephrosclerosis. 
The blood pressure of the patient was well controlled
Figure 1. (A) Retinal detachments, multiple cotton-wool spots and retinal hemorrhages noted before treatment. (B) After treatment,
retinal hemorrhages, cotton-wool spots and detachments were nearly resolved.
A Bnear 120/80 mmHg with a combination of several anti-
hypertensive medications, including a calcium-channel
blocker, an angiotensin receptor blocker and beta-
blockers. Fundoscopic examination, after 5 months
of therapy, showed near resolution of the retinal
hemorrhages, detachments and cotton-wool spots (Fig.
1B). Prednisolone (1 mg/kg/day) in combination with
intravenous cyclophosphamide (750 mg dose/month)
were administered for the lupus nephritis. The prednisolone
was slowly tapered. However, the patient could not
tolerate the serial cyclophosphamide therapy after three
treatments; the medication was changed to 100 mg of
azathioprine, 200 mg of hydroxychloroquine and 5 mg of
prednisolone to control the lupus disease activity. The
patient had a normal serum creatinine level. However, the
24-hour urine had 3,496 mg of protein. At present, the
visual acuity has recovered and the patient is stable.  
DISCUSSION
This case illustrates the course of a patient with the
unusual initial presentation of lupus nephritis with
malignant hypertension; the patient had no clinical
features of APS and hypertensive nephropathy on renal
biopsy. Malignant hypertension is characterized by
markedly elevated blood pressure associated with ischemic
retinal injury consistent with grades III or IV hypertensive
retinopathy; it is one of the most serious complications of
hypertension. In addition to the ocular features of visual
disturbance, transient ischemic attack and papilledema, it
may be associated with renal abnormalities such as
arteriolar fibrinoid necrosis and onionskin lesions, as well
as hematological abnormalities such as microangiopathic
hemolytic anemia [6]. Malignant hypertension may
develop in patients with either essential hypertension or
hypertension resulting from secondary causes related to
advanced renal parenchymal diseases such as glom-
eronephritis, scleroderma, analgesic nephropathy, or
radiation nephropathy and renovascular stenosis [3]. 
The cardiovascular manifestations associated with SLE
are variable, and include conditions such as pericarditis,
impairment of left ventricular function, early coronary
atherosclerosis, valvular heart disease, and systemic
arterial hypertension. Hypertension has not been considered
as a clinically important feature of SLE. However,
hypertension has become a major concern because it is
associated with early mortality related to the variable
atherosclerotic events or renal damage associated with
lupus nephritis. Reports on the prevalence of hypertension
in patients with SLE vary from 14% to 58.1% in different
ethnic populations [7].
There have been a number of studies correlating
the clinical features of SLE with the development of
hypertension. Among them, are reports that the development
of hypertension, in patients with SLE, was more common
in patients with advanced lupus-related renal pathology or
impairment of renal function. However, Budman and
Steinberg [7] demonstrated that the presence of significant
renal disease was not a necessary condition for the
development of hypertension; they found that the
creatinine clearance and nephritic range proteinuria
(more than 3.0 g of urine protein per 24 hours) were not
significantly different in hypertensive patients compared
to normotensive patients. 
In addition to advanced renal disease as a cause of
hypertension, anti-rheumatic drugs including corticosteroids
and cyclosporin might be associated with either the onset
or aggravation of hypertension. However, one report has
indicated no correlation between the use of corticosteroids
and hypertension [7]. Interestingly, in a retrospective
analysis of SLE patients, Kaplan et al. [8] demonstrated
that hypertension developed less frequently in patients
with rheumatoid-like arthritis than in patients without
persistent arthritis. The high dose steroid therapy, used to
treat the lupus nephritis, had no influence on the
management of hypertension in this case.
There are few reports on the clinical presentation of
malignant hypertension in patients with SLE in the
medical literature [3]. Most prior cases with malignant
hypertension occurred during the course of treatment
with high dose corticosteroids or with the development of
complicated medical issues, such as cardiac tamponade. 
Malignant hypertension is relatively more common in
SLE patients with clinical features of APS compared to the
SLE patients without APS [4]. Malignant hypertension in
APS is associated with variable renal manifestations such
as renal artery stenosis, renal infarction, thrombotic
microangiopathy, renal vein thrombosis, or glomeru-
lonephritis; these renal abnormalities mainly result from
thrombosis formation at any of the renal vessel sites [9].
For the patient presented in this report, investigations
were conducted to determine whether there was evidence
of APS. The studies included renal angiography using
computed tomography, serologic markers for lupus
anticoagulant, VDRL, β2-GP1, and anticardiolipin antibody.
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not show any of the findings compatible with APS, such as
fibrinoid necrosis or onionskin lesions. Therefore, none of
the studies performed supported the diagnosis of APS. 
SLE related retinopathy is one of most serious ocular
findings in this disease. It may lead to loss of vision in
untreated patients. Although a well-defined classification
of retinopathy has not yet been established, Giorgi et al.
[10] proposed a practical classification based on the
pathogenesis and clinical features. The association
with either lupus retinal vasculitis or atherosclerosis
suggests the “classic type” retinopathy, whereas the
Hughes’ retinopathy is related to retinal thrombosis
due to antiphospholipid bodies. Appropriate therapeutic
strategies for lupus-related retinopathy should be
determined according to the classification of retinopathy.
Immunosuppressive therapy or prophylactic low dose
aspirin can be effective for the treatment of retinal
vasculitis or atherosclerotic changes. Despite the high
dose steroid and cyclophosphamide therapy used in this
case, more than 3 months were required for improvement
of the visual acuity. This suggested that the ocular
abnormalities were due to hypertensive retinal changes
rather than a retinal vasculitis.
In conclusion, we present a case that illustrates that
hypertension may be a clinically important in the initial
diagnosis of patients with SLE and associated with the
development of diverse cardiovascular events in these
patients. Further study of the pathogenesis and clinical
effects of malignant hypertension on the courses of SLE is
needed. 
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